Download Sample, Growing Osteoarthritis Cases Boost Demand for Viscosupplementation Products
The increasing patient pool suffering from osteoarthritis, as well as the increased launch of advanced and combination drugs, are driving market expansion. According to the Centres for Disease Control and Prevention, more than 32.5 million individuals in the United States have osteoarthritis. The lifetime risk of having osteoarthritis of the knee is around 46%, whereas the lifetime risk for developing osteoarthritis of the hip is approximately 25%. As per the American Academy of Orthopaedic Surgeons' 2022 report, about 2.2 million hip and knee replacements were done in the United States. Obesity is another risk factor that contributes to orthopaedic conditions. According to the WHO, over 1 billion people globally are obese, including 650 million adults, 340 million adolescents, and 39 million children. This figure is still rising. According to WHO, by 2025, nearly 167 million adults and children will be less healthy due to being overweight or obese, resulting to an increase in the prevalence of obesity and osteoarthritis. As a result, the global expansion in the target population, combined with a rising preference for alternate corticosteroid treatment alternatives for joint pain management, is expected to considerably boost Viscosupplementation demand throughout the forecast period.
Combination of Gel Injection and Knee Bracing Help Patients with Moderate-Grade Knee Arthritis
Companies in the viscosupplementation sector are increasing treatment options for hip and hand osteoarthritis in addition to knee osteoarthritis in an effort to increase value. Manufacturers are expanding their production capacities in order to produce novel synovial fluids that thicken when pressure is applied and function as shock absorbers. The increased availability of synthetic products is propelling the viscosupplementation industry forward. This is evident due to non-animal derived products are expected to increase at an exponential rate in the market landscape. Manufacturers in the viscosupplementation sector are spreading awareness about the advantages of combining therapy like gel injection coupled with knee bracing to improve the results for patients. Gel injections have been demonstrated to be more effective when paired with knee bracing. Patients with moderate-to-severe knee arthritis benefit from this combined medication. Similarly, firms are increasing their R&D efforts to develop stem cell-based combination therapy for individuals with severe knee arthritis.
Recent Trends in Viscosupplementation Market:
- Growing preference for single-injection viscosupplementation treatments.
- Combining viscosupplementation with physical therapy and other joint treatments.
- Emerging technologies, including improved injection techniques.
- Tailoring viscosupplementation treatments to individual patient needs is gaining traction.
Explore Our Breakthrough Market Segmentation and Personalize it to Meet Your Business Needs…!
Higher Cost of Viscosupplementation Limits Market Expansion
Due to the high costs of viscosupplementation; this has become a major factor that hinders the growth of the market as it is believed to be demoralizing to low income earners. Another factor that poses a great threat to the expansion of the viscosupplementation market is the raised prices of the treatments pertaining to the condition. Such treatments, which are used for osteoarthritis in particular, are rather complex and expensive, thus limiting patient’s options and affecting market growth. Hence, the treatments bring therapeutic benefits in the treatments of disorders; however, the issue of finance might slow the extent of the treatments’ usage as well as hinder market expansion. For example, according to NCBI data, injections for viscosupplementation such as Monovisc per injection cost US$ 320; Durolane, per injection US $ 409; Synvisc-One per injection costs US$ 424; thus, high costs of viscosupplementation are expected to negatively affect market growth.
Innovations in Viscosupplementation are Enhancing Joint Treatment Efficacy and Safety
Advancements in the viscosupplementation sector are centered around improving the effectiveness and security of therapies for joints. Progress involves creating fresh formulations with enhanced viscosupplement characteristics, such as extended duration of action and improved biocompatibility. Furthermore, there is an increasing focus on enhancing delivery methods to guarantee more accurate and efficient delivery. These advancements are designed to overcome the drawbacks of old viscosupplementation items, improve patient results, and boost market expansion by providing better solutions for treating joint issues. For instance, Juniper Biologics and Kolon Life Sciences signed a licencing agreement in April 2022 to develop and commercialise TissueGene-C low dosage (TG-C LD), a non-surgical experimental treatment delivered as a single intra-articular injection, for the treatment of knee osteoarthritis.
Know Your Competitors and Strengthen Market Share Effectively
Low Production Costs Attract Manufacturers to Asia Pacific, Supporting Regional Market Growth
The Asia Pacific market is anticipated to develop rapidly throughout the forecast period due to increased healthcare expenditures. Furthermore, the low manufacturing costs in China and India have resulted in a surge in production facilities, attracting pharmaceutical and biotechnology businesses from throughout the world to the Asia-Pacific region. An increase in the incidence of rheumatoid arthritis disease is expected to fuel market development in the region over the forecast period. The market in North America is being pushed by an increasing demand for short-term interventions, even with their high cost, as well as an increase in the prevalence of disorders such as osteoarthritis. For instance, Statistics Canada estimates that the number of individuals living with arthritis in Canada would rise by 9 million by 2040. Furthermore, according to the Centres for Disease Control and Prevention (CDC), almost one in every four United States adults (23.7%), or around 58.5 million individuals, has doctor-diagnosed arthritis. Thus, as the number of individuals suffering from arthritis and knee pain grows, will increase the demand for viscosupplementation, which is likely to drive market growth throughout the forecast period.
Searching for a Country or Region-Specific Report?
Unlock industry complexities with reports crafted for selected countries and regions at Reduced Cost
The report provides a detailed overview of the viscosupplementation market insights in regions including North America, Latin America, Europe, Asia-Pacific, Oceania, and the Middle East and Africa. The country-specific assessment for viscosupplementation market has been offered for all regional market share, along with forecasts, market scope estimates, price point assessment, and impact analysis of prominent countries and regions. Throughout this market research report, Y-o-Y growth and CAGR estimates are also incorporated for every country and region, to provide a detailed view of the viscosupplementation market. These Y-o-Y projections on regional and country-level markets brighten the political, economic and business environment outlook, which are anticipated to have a substantial impact on the growth of the viscosupplementation market. Some key country and region included in the viscosupplementation market report as follows:
| Regions | Countries |
|---|---|
| North America | United States, Canada |
| Latin America | Brazil, Mexico, Argentina, Colombia, Chile, Rest of Latin America |
| Europe | Germany, United Kingdom, France, Italy, Spain, Russia, Netherlands, Switzerland, Belgium, Sweden, Austria, Norway, Denmark, Finland, Ireland, Czech Republic, Rest of Europe |
| Asia Pacific | China, India, Japan, South Korea, Australia & New Zealand, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia Pacific |
| Middle East and Africa | GCC Countries, South Africa, Egypt, Turkey, Morocco, Israel, Iran, Kenya, Nigeria, Rest of MEA |
Viscosupplementation Market Research Report Covers In-depth Analysis on:
- Viscosupplementation market detailed segments and segment-wise market breakdown
- Viscosupplementation market dynamics (Recent industry trends, drivers, restraints, growth potential, opportunities in viscosupplementation industry)
- Current, historical and forthcoming 10 years market valuation in terms of viscosupplementation market size (US$ Mn), volume (Units), share (%), Y-o-Y growth rate, CAGR (%) analysis
- Viscosupplementation market demand analysis
- Viscosupplementation market pricing analysis over forecast period (by key segment and by region)
- Viscosupplementation market regional insights with region-wise market breakdown
- Competitive analysis – key companies profiling including their market share, product offerings, and competitive strategies.
- Latest developments and innovations in viscosupplementation market
- Regulatory landscape by key regions and key countries
- Supply chain and value chain analysis in viscosupplementation market
- Viscosupplementation market sales and distribution strategies
- A comprehensive overview of parent market
- A detailed viewpoint on viscosupplementation market forecast by countries
- Mergers and acquisitions in viscosupplementation market
- Essential information to enhance market position
- Robust research methodology
- Frequently Asked Questions -
What factors are driving the growth of the viscosupplementation market?
Increasing geriatric populations, rising prevalence of osteoarthritis and advancements in minimally invasive procedures are significant factors propelling the growth of the viscosupplementation market.
What is the market outlook for viscosupplementation over the next decade?
The viscosupplementation market is expected to experience steady growth, driven by advancements in technology, increased patient awareness and the rising incidence of osteoarthritis.
How does viscosupplementation compare to traditional treatments for joint pain?
Viscosupplementation provides a more targeted approach than traditional treatments like NSAIDs, offering longer-lasting relief and potentially reducing the need for surgery in some patients.
